Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 01/08/22
End: 09/12/22
Due: 09/12/23
Phase: N/A
Priority: Normal
Start: 11/01/22
End: 12/31/24
Due: 12/31/25
Phase: N/A
Priority: Normal
Start: 01/01/24
End: 12/31/27
Due: 12/31/28
Phase: N/A
Priority: Normal
Start: 10/01/23
End: 03/31/27
Due: 03/31/28
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Comparison of Oral Lactulose Versus Polyethylene Glycol for Bowel Preparation in Low-risk Patients | NCT05648318 | Zhang Xiaofeng,MD | user2@example.com | None | 2022-01-08 | 2022-09-12 | 2023-09-12 | - | - | 2025-07-14 |
| A RCT of the Efficacy of Tegoprazan 50mg QD in the Treatment of Helicobacter Pylori Infection ( TATH-1 ) | NCT05647278 | Zhang Xiaofeng,MD | user2@example.com | None | 2022-11-01 | 2024-12-31 | 2025-12-31 | - | - | 2025-07-14 |
| Early Phase I Study of Autologous T Cells (EX02 CAR-T) for Unresectable Pancreatic/Bile Duct Cancer | NCT06196658 | Zhang Xiaofeng,MD | user2@example.com | None | 2024-01-01 | 2027-12-31 | 2028-12-31 | - | - | 2025-07-14 |
| Canagliflozin With Gemcitabine in Pancreatic Carcinoma | NCT05903703 | Zhang Xiaofeng,MD | user2@example.com | None | 2023-10-01 | 2027-03-31 | 2028-03-31 | - | - | 2025-07-14 |